(FDMT) 4D Molecular Therapeutics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US35104E1001

Stock: Gene Therapy, Drug Development, Vector Platform

Total Rating 53
Risk 85
Buy Signal -0.08
Biotechnology +8.1
Biotechnology +6.7
Market Cap: 494m
Avg Trading Vol: 6.19M USD
ATR: 7.20%
Peers RS (IBD): 60.3
Risk 5d forecast
Volatility 88.0%
Relative Tail Risk -12.5%
Reward TTM
Sharpe Ratio 1.21
Alpha 89.50
Character TTM
Beta 1.098
Beta Downside 0.900
Drawdowns 3y
Max DD 93.00%
CAGR/Max DD -0.22

EPS (Earnings per Share)

EPS (Earnings per Share) of FDMT over the last years for every Quarter: "2021-03": -0.61, "2021-06": -0.28, "2021-09": -0.82, "2021-12": -0.85, "2022-03": -0.82, "2022-06": -0.87, "2022-09": -0.79, "2022-12": -0.84, "2023-03": -0.88, "2023-06": -0.77, "2023-09": -0.24, "2023-12": -0.75, "2024-03": -0.66, "2024-06": -0.63, "2024-09": -0.79, "2024-12": -0.9, "2025-03": -0.86, "2025-06": -0.98, "2025-09": -1.01, "2025-12": 0,
EPS CAGR: 45.03%
EPS Trend: 21.1%
Last SUE: 4.00
Qual. Beats: 1

Revenue

Revenue of FDMT over the last years for every Quarter: 2021-03: 2, 2021-06: 14.58, 2021-09: 1.366, 2021-12: 0.092, 2022-03: 1.219, 2022-06: 0.162, 2022-09: 0.5, 2022-12: 1.247, 2023-03: 0.298, 2023-06: 0.239, 2023-09: 20.204, 2023-12: -0.019, 2024-03: 0.028, 2024-06: 0.005, 2024-09: 0.003, 2024-12: 0.001, 2025-03: 0.014, 2025-06: 0.015, 2025-09: 0.09, 2025-12: null,
Rev. CAGR: -0.58%
Rev. Trend: -24.2%
Last SUE: -0.08
Qual. Beats: 0

Risks

Technicals: choppy

Description: FDMT 4D Molecular Therapeutics March 05, 2026

4D Molecular Therapeutics Inc. (FDMT) is a late-stage biotechnology company specializing in gene therapy development.

Their core business model involves using a proprietary platform, Therapeutic Vector Evolution, to develop adeno-associated virus (AAV) vectors. AAV gene therapies are a key area of focus in the biotechnology sector due to their potential for long-term therapeutic effects from a single administration.

Their lead candidate, 4D-150, targets retinal vascular diseases like wet age-related macular degeneration and diabetic macular edema. This involves sustained production of anti-VEGF proteins directly in the retina. The company also has a pipeline of other gene therapy candidates for conditions such as cystic fibrosis, geographic atrophy, alpha-1 anti-trypsin deficiency lung disease, and Fabry disease, all in various stages of development from preclinical to Phase 1 clinical trials.

FDMT engages in collaborations and licensing agreements with other biotechnology and pharmaceutical companies, a common strategy in the capital-intensive drug development industry to share risks and resources.

To further understand FDMTs market position and future prospects, consider exploring additional data and analytics on ValueRay.

Headlines to watch out for

  • 4D-150 clinical trial results impact future revenue potential
  • Pipeline development costs strain company financials
  • Regulatory approval for gene therapies poses significant risk
  • Collaboration agreements provide non-dilutive funding

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: -209.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.44 > 0.02 and ΔFCF/TA -24.32 > 1.0
NWC/Revenue: 229.4k% < 20% (prev 2.83m%; Δ -2.60m% < -1%)
CFO/TA -0.43 > 3% & CFO -183.5m > Net Income -209.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.42 > 1.5 & < 3
Outstanding Shares: last quarter (56.1m) vs 12m ago 1.03% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.02% > 50% (prev 0.00%; Δ 0.02% > 0%)
Interest Coverage Ratio: -13.38 > 6 (EBITDA TTM -226.8m / Interest Expense TTM -16.9m)

Altman Z'' -15.00

A: 0.65 (Total Current Assets 312.4m - Total Current Liabilities 37.1m) / Total Assets 424.0m
B: -1.74 (Retained Earnings -735.7m / Total Assets 424.0m)
C: -0.44 (EBIT TTM -226.1m / Avg Total Assets 514.0m)
D: -13.36 (Book Value of Equity -735.0m / Total Liabilities 55.0m)
Altman-Z'' Score: -18.39 = D

Beneish M

DSRI: none (Receivables none/none, Revenue 120.0k/17.0k)
GMI: 1.00 (fallback, negative margins)
AQI: 2.11 (AQ_t 0.18 / AQ_t-1 0.09)
SGI: 7.06 (Revenue 120.0k / 17.0k)
TATA: -0.06 (NI -209.2m - CFO -183.5m) / TA 424.0m)
Beneish M-Score: cannot calculate (missing components)

What is the price of FDMT shares?

As of March 10, 2026, the stock is trading at USD 8.73 with a total of 552,919 shares traded.
Over the past week, the price has changed by -6.43%, over one month by -3.85%, over three months by -16.94% and over the past year by +124.13%.

Is FDMT a buy, sell or hold?

4D Molecular Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy FDMT.
  • StrongBuy: 5
  • Buy: 4
  • Hold: 2
  • Sell: 0
  • StrongSell: 1

What are the forecasts/targets for the FDMT price?

Issuer Target Up/Down from current
Wallstreet Target Price 33.1 279.3%
Analysts Target Price 33.1 279.3%

FDMT Fundamental Data Overview March 07, 2026

P/S = 4113.7256
P/B = 1.2331
Revenue TTM = 120.0k USD
EBIT TTM = -226.1m USD
EBITDA TTM = -226.8m USD
Long Term Debt = 22.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.70m USD (from shortTermDebt, last quarter)
Debt = 22.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.3m USD (from netDebt column, last quarter)
Enterprise Value = 210.8m USD (493.6m + Debt 22.3m - CCE 305.1m)
Interest Coverage Ratio = -13.38 (Ebit TTM -226.1m / Interest Expense TTM -16.9m)
EV/FCF = -1.14x (Enterprise Value 210.8m / FCF TTM -185.1m)
FCF Yield = -87.77% (FCF TTM -185.1m / Enterprise Value 210.8m)
FCF Margin = -154.2k% (FCF TTM -185.1m / Revenue TTM 120.0k)
Net Margin = -174.3k% (Net Income TTM -209.2m / Revenue TTM 120.0k)
Gross Margin = unknown ((Revenue TTM 120.0k - Cost of Revenue TTM 97.0m) / Revenue TTM)
Tobins Q-Ratio = 0.50 (Enterprise Value 210.8m / Total Assets 424.0m)
Interest Expense / Debt = 6.34% (Interest Expense 1.41m / Debt 22.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -178.6m (EBIT -226.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.42 (Total Current Assets 312.4m / Total Current Liabilities 37.1m)
Debt / Equity = 0.06 (Debt 22.3m / totalStockholderEquity, last quarter 369.0m)
Debt / EBITDA = 0.12 (negative EBITDA) (Net Debt -26.3m / EBITDA -226.8m)
Debt / FCF = 0.14 (negative FCF - burning cash) (Net Debt -26.3m / FCF TTM -185.1m)
Total Stockholder Equity = 442.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.70% (Net Income -209.2m / Total Assets 424.0m)
RoE = -47.27% (Net Income TTM -209.2m / Total Stockholder Equity 442.6m)
RoCE = -48.64% (EBIT -226.1m / Capital Employed (Equity 442.6m + L.T.Debt 22.3m))
RoIC = -40.36% (negative operating profit) (NOPAT -178.6m / Invested Capital 442.6m)
WACC = 9.75% (E(493.6m)/V(515.9m) * Re(9.96%) + D(22.3m)/V(515.9m) * Rd(6.34%) * (1-Tc(0.21)))
Discount Rate = 9.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.76%
[DCF] Fair Price = unknown (Cash Flow -185.1m)
EPS Correlation: 21.09 | EPS CAGR: 45.03% | SUE: 4.0 | # QB: 1
Revenue Correlation: -24.20 | Revenue CAGR: -0.58% | SUE: -0.08 | # QB: 0
EPS next Year (2026-12-31): EPS=-3.48 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+5 | Growth EPS=-6.8% | Growth Revenue=-40.2%

Additional Sources for FDMT Stock

Fund Manager Positions: Dataroma | Stockcircle